BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 [PMID: 25848461 DOI: 10.4254/wjh.v7.i3.315]
URL: https://www.wjgnet.com/1948-5182/full/v7/i3/315.htm
Number Citing Articles
1
R.B. Prussick, L. Miele. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?British Journal of Dermatology 2018; 179(1): 16 doi: 10.1111/bjd.16239
2
Chunwei Cheng, Jun Tan, Wei Qian, Lei Zhang, Xiaohua Hou. Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunctionLife Sciences 2018; 209: 157 doi: 10.1016/j.lfs.2018.08.017
3
J.M. Carrascosa, C. Bonanad, E. Dauden, R. Botella, A. Olveira-Martín. Psoriasis e hígado graso no alcohólicoActas Dermo-Sifiliográficas 2017; 108(6): 506 doi: 10.1016/j.ad.2016.12.017
4
Yuhei Aotani, Yuta Kumagai, Masanobu Kameda, Kenji Wada, Toshiyuki Matsunaka, Hiroyasu Morikawa, Hiromichi Horinaka. Improvement of a combined ultrasonic probe used in ultrasonic velocity-change method for evaluation of fat contentJapanese Journal of Applied Physics 2018; 57(7S1): 07LF18 doi: 10.7567/JJAP.57.07LF18
5
Oriana Simonetti, Giulio Rizzetto, Elisa Molinelli, Federico Diotallevi, Giulia Radi, Oscar Cirioni, Marcello Mario D’Errico, Annamaria Offidani. Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological SettingHealthcare 2021; 9(4): 401 doi: 10.3390/healthcare9040401
6
Gyongyi Szabo, Timea Csak. Role of MicroRNAs in NAFLD/NASHDigestive Diseases and Sciences 2016; 61(5): 1314 doi: 10.1007/s10620-015-4002-4
7
J.M. Carrascosa, C. Bonanad, E. Dauden, R. Botella, A. Olveira-Martín. Psoriasis and Nonalcoholic Fatty Liver DiseaseActas Dermo-Sifiliográficas (English Edition) 2017; 108(6): 506 doi: 10.1016/j.adengl.2017.05.017
8
Xin Sun, Yan Zhang, Meilin Xie. The role of peroxisome proliferator-activated receptor in the treatment of non-alcoholic fatty liver diseaseActa Pharmaceutica 2017; 67(1): 1 doi: 10.1515/acph-2017-0007
9
Lisa B. VanWagner, Mary E. Rinella. Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseCurrent Hepatology Reports 2016; 15(2): 75 doi: 10.1007/s11901-016-0295-9
10
Antonio Benedetti, Anna Campanati, Emanuela Martina, Oriana Simonetti, Emanuele Bendia, Antonio Di Sario, Luca Maroni, Marco Marzioni, Irene Pierantonelli, Paola Sassaroli, Laura Schiadà, Gianluca Svegliati-Baroni, Giuseppe Tarantino, Annamaria Offidani. The First Outstanding 50 Years of “Università Politecnica delle Marche”2020; : 221 doi: 10.1007/978-3-030-33832-9_16
11
Pasinee Rongngern, Leena Chularojanamontri, Chanisada Wongpraparut, Narumol Silpa-Archa, Watcharasak Chotiyaputta, Ananya Pongpaibul, Phunchai Charatcharoenwitthaya. Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective studyArchives of Dermatological Research 2017; 309(5): 403 doi: 10.1007/s00403-017-1733-4
12
Stefano Ballestri, Alessandro Mantovani, Fabio Nascimbeni, Simonetta Lugari, Amedeo Lonardo. Extra-hepatic manifestations and complications of nonalcoholic fatty liver diseaseFuture Medicinal Chemistry 2019; 11(16): 2171 doi: 10.4155/fmc-2019-0003
13
Ivana Mikolasevic, Sandra Milic, Tamara Turk Wensveen, Ivana Grgic, Ivan Jakopcic, Davor Stimac, Felix Wensveen, Lidija Orlic. Nonalcoholic fatty liver disease - A multisystem disease?World Journal of Gastroenterology 2016; 22(43): 9488-9505 doi: 10.3748/wjg.v22.i43.9488
14
Talat Bessissow, Ngoc Han Le, Kathleen Rollet, Waqqas Afif, Alain Bitton, Giada Sebastiani. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases 2016; 22(8): 1937 doi: 10.1097/MIB.0000000000000832
15
M. A. Livzan, O. V. Gaus, N. A. Nikolaev, T. S. Krolevetz. NAFLD: comorbidity and associated diseasesExperimental and Clinical Gastroenterology 2020; 1(10): 57 doi: 10.31146/1682-8658-ecg-170-10-57-65
16
Valerio Rosato, Mario Masarone, Marcello Dallio, Alessandro Federico, Andrea Aglitti, Marcello Persico. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic SyndromeInternational Journal of Environmental Research and Public Health 2019; 16(18): 3415 doi: 10.3390/ijerph16183415
17
Andrew A. Li, Aijaz Ahmed, Donghee Kim. Extrahepatic Manifestations of Nonalcoholic Fatty Liver DiseaseGut and Liver 2020; 14(2): 168 doi: 10.5009/gnl19069
18
Naif O. Al-Harbi, Ahmed Nadeem, Mohammed M. Al-Harbi, Khairy M.A. Zoheir, Mushtaq A. Ansari, Ahmed M. El-Sherbeeny, Khalid M. Alanazi, Moureq R. Alotaibi, Sheikh F. Ahmad. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine modelImmunobiology 2017; 222(2): 128 doi: 10.1016/j.imbio.2016.10.013
19
Maria Chondronikola, Souvik Sarkar. Total-body PET ImagingPET Clinics 2021; 16(1): 75 doi: 10.1016/j.cpet.2020.09.001
20
Emma Coussens, Lynda Grine, Jessica Bostoen, Herman Mielants, Jo Lambert. Analysis of telomere length as predictive marker in psoriasis for comorbiditiesExperimental Dermatology 2016; 25(5): 388 doi: 10.1111/exd.12959
21
A. Campanati, D. Benfaremo, M. M. Luchetti, G. Ganzetti, A. Gabrielli, A. Offidani. Certolizumab pegol for the treatment of psoriasisExpert Opinion on Biological Therapy 2017; 17(3): 387 doi: 10.1080/14712598.2017.1283401
22
Dan Ilkovitch, Laura K. Ferris. Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various moleculesMolecular Medicine Reports 2016; 14(4): 3935 doi: 10.3892/mmr.2016.5685
23
Che-Yung Chao, Robert Battat, Alex Al Khoury, Sophie Restellini, Giada Sebastiani, Talat Bessissow. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review articleWorld Journal of Gastroenterology 2016; 22(34): 7727-7734 doi: 10.3748/wjg.v22.i34.7727
24
M. Munera-Campos, J. Vilar-Alejo, R. Rivera, J. M. Carrascosa, E. Daudén, E. Herrera-Acosta, A. Sahuquillo-Torralba, F. J. Gómez-García, O. Baniandrés-Rodríguez, P. de la Cueva, J. L. López-Estebaranz, I. Belinchón, M. Ferran, J. Riera-Monroig, L. Rodriguez, G. Carretero, C. García-Donoso, F. Ballescá, M. Llamas-Velasco, E. Herrera-Ceballos, C. Pujol-Marco, L. M. Nieto-Benito, D. P. Ruiz-Genao, M. Alsina, M. A. Descalzo, I. García-Doval. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registryJournal of Dermatological Treatment 2021; : 1 doi: 10.1080/09546634.2021.1922572
25
J. Albrecht, S. Gerdes. A new option on the horizon for the treatment of psoriasis: it is needed, but not at any priceBritish Journal of Dermatology 2016; 174(6): 1183 doi: 10.1111/bjd.14712
26
José María G. Ruiz de Morales, Lluís Puig, Esteban Daudén, Juan D. Cañete, José Luis Pablos, Antonio Olveira Martín, Carlos González Juanatey, Alfredo Adán, Xavier Montalbán, Natalia Borruel, Guillermo Ortí, Esther Holgado-Martín, Carolina García-Vidal, Cynthia Vizcaya-Morales, Víctor Martín-Vázquez, Miguel Ángel González-Gay. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversiesAutoimmunity Reviews 2020; 19(1): 102429 doi: 10.1016/j.autrev.2019.102429
27
Anna Campanati, Matteo Paolinelli, Frederico Diotallevi, Emanuela Martina, Elisa Molinelli, Annamaria Offidani. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasisExpert Opinion on Drug Metabolism & Toxicology 2019; 15(11): 913 doi: 10.1080/17425255.2019.1681969
28
M. A. Koroleva. Hepatocorbidity in psoriasisMedical alphabet 2021; (9): 7 doi: 10.33667/2078-5631-2021-9-7-11
29
Muzahir Hussain, Muhammad Umair Ijaz, Muhammad Ijaz Ahmad, Iftikhar Ali Khan, Syed Umar Farooq Bukhary, Waqar Khan, Sayed Hussain, Majid Suhail Hashmi, Chunbao Li. Gut inflammation exacerbates hepatic injury in C57BL/6J mice via gut-vascular barrier dysfunction with high-fat-incorporated meat protein dietsFood & Function 2020; 11(10): 9168 doi: 10.1039/D0FO02153A